On ECHEMI
Home > Drugs > Apridin Hydrochloride Tablets

Apridin Hydrochloride Tablets

Function and Efficacy

This product belongs to Class Ib antiarrhythmic drugs, inhibits the permeability of cell membrane to Na, but does not promote K outflow. It can slow down the conduction of various parts of the cardiac conduction system, reduce membrane reactivity, increase the excitation threshold, prolong the effective adaptation period of the atrium, atrioventricular node, His-Purkinje system (Purkinjes fibers) and ventricle, and block the forward and reverse conduction of the bypass pathway.

Ingredients

Aprindine hydrochloride. Chemical name: N, N'-diethyl-N'-2-indanyl-N'-phenyl-1,3-propylenediamine monohydrochloride.

Name Description Content CAS NO. Manufacturer
APRINDINE HCLIngredients

This product belongs to Class Ib antiarrhythmic drugs, inhibits the permeability of cell membrane to Na, but does not promote K outflow. It can slow down the conduction of various parts of the cardiac conduction system, reduce membrane reactivity, increase the excitation threshold, prolong the effective adaptation period of the atrium, atrioventricular node, His-Purkinje system (Purkinjes fibers) and ventricle, and block the forward and reverse conduction of the bypass pathway.

More
33237-74-0 2

Appearance

This product is a sugar-coated tablet, which appears off-white after removing the sugar coating.

Indication

Used for frequent ventricular and atrial premature contractions, paroxysmal ventricular and atrial tachycardia, preexcitation syndrome, tachycardia, etc.

Usage and Dosage

Oral. Adults: Generally 100 mg (4 tablets) for the first dose, 50-100 mg (2-4 tablets) for the next 6-8 hours, no more than 300 mg (12 tablets) for the day, 100-150 mg (4-6 tablets) each for 2-3 days, divided into 2-3 doses, then gradually reduced to the maintenance dose, which is 50-100 mg (2-4 tablets) per day. Children and the elderly: Reduce the dosage as appropriate, or follow the doctor's advice.

Adverse Reactions

Individual patients may experience vertigo, ataxia, paresthesia, hallucinations, diplopia, memory impairment, and hand tremors. In severe cases, epileptic convulsions may occur, and nausea, vomiting, and diarrhea may also be seen. Occasionally, idiosyncratic reactions such as elevated ALT, cholestatic jaundice, and agranulocytosis may occur.

Precautions

1. Patients with moderate or severe atrioventricular conduction delay and severe intraventricular conduction delay are prohibited from using this product. 2. Patients with a history of epileptic seizures are prohibited from using this product. 3. Patients with jaundice or abnormal blood count are prohibited from using this product. 4. Patients with severe heart failure are prohibited from using this product. 5. Patients who are allergic to this product are prohibited from using this product.

Special Population Medication

Precautions for children: Not clear. Precautions for pregnancy and lactation: Use with caution. Precautions for the elderly: Use with caution.

Drug Interactions

When procaine or lidocaine is used for infiltration anesthesia at the same time, the drug should be discontinued or the dosage should be reduced for 2 to 3 days. It should not be used together with other antiarrhythmic drugs.

Storage

Keep in a light-proof and sealed container. Validity period: 24 months.

Packaging Specification

25 mg

Validity Period

24 months

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.